



6976-91349 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

App. No. : 10/762,616
Applicant : HERNANDEZ-RAMIREZ, Luisa
Filed : 22 January 2004
Art Unit : 1617
Examiner : HUYNH, Carlic K.
Docket No. : 6976-91349
Customer No. : 24628
Title : ASSOCIATION OF
FLUCONAZOLE-TINIDAZOLE FOR THE
TREATMENT OF VAGINAL INFECTIONS,
ITS COMPOSITION, PREPARATION
PROCESS AND USAGE

Confirmation No.: 5023

**CERTIFICATE OF MAILING BY
FIRST CLASS MAIL (37 CFR 1.8)**

I hereby certify that this correspondence is
being deposited with the United States
Postal Service with sufficient postage as
First Class Mail in an envelope addressed
to: Mail Stop Amendment, Commissioner
for Patents, P.O. Box 1450, Alexandria, VA
22313, on the date below

Carlic K. Huynh

21 March 2008
(Date)

AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

The Office Action of October 9, 2007 has been carefully reviewed and the following
amendments and remarks are made in response thereto:

7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Previously Presented) The pharmaceutical composition according to Claim 1, characterized by a percent by weight of $75\% \pm 20\%$ tinidazole and a percent by weight of $6\% \pm 2\%$ fluconazole.
14. (Cancelled)
15. (Previously Presented) The pharmaceutical composition according to Claim 14, characterized by a tablet form.
16. (Previously Presented) The pharmaceutical composition according to Claim 1, characterized by a vehicle mixture of acceptable pharmaceutical vehicles that comprises microcrystalline cellulose, sodium glycolate of starch, polyvinylpyrrolidone, magnesium stearate and white opadry.

17. (Previously Presented) The pharmaceutical composition according to Claim 1, characterized by a percent by weight of 75% tinidazole.

18. (Previously Presented) The pharmaceutical composition according to Claim 2, characterized by a percent by weight of 75% secnidazole.

19. (Previously Presented) The pharmaceutical composition according to Claim 1, characterized by a percent by weight of 5.7% fluconazole.

20. (Previously Presented) The pharmaceutical composition according to Claim 2, characterized by a percent by weight of 5.7% fluconazole.

21. (Previously Presented) The pharmaceutical composition according to Claim 1, wherein the composition is characterized by about 112.5 mg of fluconazole and about 1.5 g of tinidazole.

22. (Previously Presented) The pharmaceutical composition according to Claim 2, wherein the composition is characterized by about 112.5 mg of fluconazole and about 1.5 g of secnidazole.